Reuters logo
BRIEF-Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T‑cells
May 25, 2017 / 12:15 PM / in 5 months

BRIEF-Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T‑cells

May 25 (Reuters) - Adaptimmune Therapeutics Plc

* Adaptimmune Therapeutics Plc - initiated study of NY-ESO SPEAR T-cells targeting NY-ESO in combination with keytruda in patients with multiple myeloma

* Adaptimmune Therapeutics Plc - Adaptimmune is developing NY-ESO SPEAR T-cell program under a strategic collaboration agreement with GSK Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below